Detection of cancer in patients by reduced lymphocytic cortisol metabolism-enhancing effect.
A double-blind study was done on the plasma from 59 hospitalized patients to determine whether a diminished lymphocytic cortisol metabolism-enhancing effect among cancer patients could be used to distinguish them from persons with noncancerous diseases. Known concentrations of human lymphocytes from healthy donors were incubated with cortisol in media containing 50% phosphate-buffered saline (PBS) and 50% of one of the following additives: 1) homologous plasma (HP), 2) plasma from the patient being tested, or 3) additional PBS. Plasma in which the metabolism-enhancing effect was less than 70% of that obtained with HP was considered to be that of a cancer patient. Among the 19 patients known to have cancer, there were only two false-negative results, whereas among the 40 patients diagnosed as having noncancerous diseases, there were six false-positive results. Thus the test findings and the pathologic diagnosis were obviously correlated in approximately 90% of the patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism*; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000175:diagnosis*
D006854:Hydrocortisone